Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IMPACT-CMH: Impact of Mitral Valve and Subvalvular Abnormalities in Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten

NCT07716826 is registered in ClinicalTrials.gov with French Cardiology Society as lead sponsor.

NCT NCT07716826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07716826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IMPACT-CMH: Impact of Mitral Valve and Subvalvular Abnormalities in Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten
Lead sponsor
French Cardiology Society
Phase
Observational
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
December 31, 2026
Enrollment
150 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cardiomyopathy, hypertrophic obstructive